NCT01736917 - Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

June 30, 2015

Conditions

Chemotherapy-Induced Nausea and Vomiting

Interventions

DRUG

Fosaprepitant

Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis

DRUG

Dexamethasone

Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8

DRUG

5HT3

Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.

Trial Locations (4)

MUSC Hollings Cancer Center, Charleston

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Siteman Cancer Center, St Louis

Nebraska Cancer Specialists, Omaha